Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Evolus says its Botox biosimilar could be delayed by FDA issues with Daewoong plant
Evolus says its Botox biosimilar could be delayed by FDA issues with Daewoong plant
Evolus says its Botox biosimilar could be delayed by FDA issues with Daewoong plant
Submitted by
admin
on January 25, 2018 - 5:56pm
Source:
Fierce Pharma
News Tags:
Evolus
Botox
biosimilars
FDA
drug manufacturing
Headline:
Evolus says its Botox biosimilar could be delayed by FDA issues with Daewoong plant
Do Not Allow Advertisers to Use My Personal information
